Aprea Therapeutics, Inc. announced on August 23, 2023, Christian S. Schade resigned from the Board of Directors including as Chairperson of the Board and any respective committee of the Board to which he was a member, effective immediately. The resignation was not the result of any disagreements with the Company relating to the Company?s operations, policies or practices. Following Mr. Schade?s resignation, on August 23, 2023, the Board appointed Richard Peters, M.D., Ph.D., to serve as Chairperson of the Board, effective immediately.

Following Mr. Schade?s resignation, on August 23, 2023, the Board appointed Dr. Jean-Pierre Bizzari as a Class III director, effective immediately, to serve until the Company?s 2025 annual meeting of stockholders or until his earlier resignation or removal. The Board did not appoint Dr. Bizzari to any of the Board?s committees, although the Board may appoint him to one or more committees in the future. Dr. Bizzari will participate in the Company?s non-employee director compensation arrangement (described in the Company's proxy statement filed with the Securities and Exchange Commission on July 11, 2023), as may be amended from time to time.

Dr. Bizzari, age 68, currently serves on the board of directors of Halozyme Therapeutics, ADC Therapeutics, NETRIS Pharma, and Oxford BioTherapeutics, where he has served since 2015, 2021, 2021 and 2016, respectively. Dr. Bizzari is a member and leader on many scientific committees and is currently a member of the Scientific Advisory Board for the National Cancer Institute in France; a Board member of the European Organization of Research and Treatment of Cancer (EORTC) and Chairman of the EORTC New Drug Advisory Committee. Most recently, Dr. Bizzari was the Group Head Clinical Development Oncology at Celgene.

He led global clinical development conducting over 25 Phase 3 trials, was responsible for global operations of over 950 people and was Chairman of the Hematology Oncology development committee. Prior to Celgene, Dr. Bizzari was the VP of clinical development oncology at Sanofi-Aventis where he was responsible for the worldwide clinical development and approvals. He also served as VP of clinical development oncology at Rhone-Poulenc Rorer where he shepherded a deep pipeline of oncology candidates.

Dr. Bizzari holds a degree in mathematics, and completed his medical studies in Nice, France. He completed his residency in oncology at Pitie Salpetriere Hospital in Paris.